Ahonen Matti, Ala-Aho Risto, Baker Andrew H, George Sarah J, Grénman Reidar, Saarialho-Kere Ulpu, Kähäri Veli-Matti
Centre for Biotechnology, University of Turku and Abo Akademi University, Turku, Finland.
Mol Ther. 2002 Jun;5(6):705-15. doi: 10.1006/mthe.2002.0606.
We have studied the effect of a newly identified tumor suppressor tissue inhibitor of metalloproteinases- 3 (TIMP-3) on the growth of human melanoma and squamous-cell carcinoma (SCC). Adenoviral delivery of the TIMP-3 gene to human melanoma (A2058) and SCC (UT-SCC-7) cells ex vivo inhibited tumorigenesis after subcutaneous (s.c.) injection of the infected cells into SCID/SCID mice. Three daily consecutive intratumoral injections of 1.4x10(9) plaque-forming units (pfu) of TIMP-3 adenovirus (RAdTIMP-3) inhibited the growth of preestablished melanoma and SCC xenografts in SCID/SCID mice, whereas growth of control virus-injected tumors was not affected. The antitumor effect of RAdTIMP-3 was obtained with in vivo adenoviral transduction efficiency of 8-10%, and it was more potent than that of adenovirally delivered p53. Adenovirusmediated expression of TIMP-3 potently reduced gelatinolytic activity, increased the number of apoptotic cells, and inhibited vascularization of melanomas. Escalation of the adenoviral dose to three rounds of three daily consecutive injections with 1.4x10(9) pfu of RAdTIMP-3 every 6 days entirely inhibited growth of injected melanomas for 32 days. Mixing RAdTIMP-3-infected A2058 cells with uninfected cells in 1:1 ratio in culture resulted in death of all cells in 96 hours. Adenovirally delivered TIMP-3 was also expressed by A2058 cells in soluble form into the culture medium, where it exerted a cytotoxic effect on uninfected A2058 cell cultures after relocating to the cell layer. These results identify TIMP-3 as a novel type of secreted tumor suppressor, which has antiinvasive, antiangiogenic, and proapoptotic effects in vivo, and which displays a potent bystander effect validating further exploration of its applicability in human cancer gene therapy.
我们研究了新发现的肿瘤抑制因子金属蛋白酶组织抑制剂-3(TIMP-3)对人黑色素瘤和鳞状细胞癌(SCC)生长的影响。将TIMP-3基因通过腺病毒载体在体外导入人黑色素瘤(A2058)和SCC(UT-SCC-7)细胞后,将感染的细胞皮下注射到SCID/SCID小鼠体内可抑制肿瘤发生。连续三天每天瘤内注射1.4×10⁹ 空斑形成单位(pfu)的TIMP-3腺病毒(RAdTIMP-3)可抑制SCID/SCID小鼠体内已形成的黑色素瘤和SCC异种移植物的生长,而注射对照病毒的肿瘤生长未受影响。RAdTIMP-3的抗肿瘤作用在体内腺病毒转导效率为8 - 10%时即可获得,且比腺病毒介导的p53更有效。腺病毒介导的TIMP-3表达可有效降低明胶酶活性,增加凋亡细胞数量,并抑制黑色素瘤的血管生成。将腺病毒剂量增加至每6天连续三天每天注射1.4×10⁹ pfu的RAdTIMP-3,共进行三轮,可在32天内完全抑制注射的黑色素瘤生长。在培养中将RAdTIMP-3感染的A2058细胞与未感染细胞按1:1比例混合,96小时内所有细胞均死亡。腺病毒介导的TIMP-3也以可溶性形式由A2058细胞分泌到培养基中,转移至细胞层后对未感染的A2058细胞培养物发挥细胞毒性作用。这些结果表明TIMP-3是一种新型的分泌型肿瘤抑制因子,在体内具有抗侵袭、抗血管生成和促凋亡作用,并显示出强大的旁观者效应,这为进一步探索其在人类癌症基因治疗中的适用性提供了依据。